Pegaptanib sodium (Macugen™) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF) 165 , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF 121 . Aft er more than 10 years in development and preclinical study, pegaptanib was shown in clinical trials to be eff ective in treating choroidal neovascularization associated with age-related macular degeneration. Its excellent ocular and systemic safety proÞ le has also been conÞ rmed in patients receiving up to three years of therapy. Early, wellcontrolled studies further suggest that pegaptanib may provide therapeutic beneÞ t for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. Notably, pegaptanib was the Þ rst available aptamer approved for therapeutic use in humans and the Þ rst VEGF inhibitor available for the treatment of ocular vascular diseases.
Studies of the pathophysiology of neovascular diseases of the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), have demonstrated a central role for vascular endothelial growth factor (VEGF; also known as VEGF-A) in the pathogenesis of these disorders. VEGF acts as a master regulator and promoter of angiogenesis 1 and is also the most potent known promoter of vascular permeability.
2
Ocular VEGF concentrations were found to be elevated in the eyes of patients suffering from neovascularizing conditions and preclinical studies showed that VEGF was both necessary and suffi cient for the development of ocular neovascularization. 3 These studies provided compelling evidence for the use of VEGF inhibitors in treating AMD patients. 4 This review focuses entirely on pegaptanib (for more detailed reviews see Ng et al. 3 ; Cunningham et al. 5 ).
Symposium

Development of Pegaptanib
Pegaptanib was developed in the 1990s using the SELEX (selective evolution of ligands by exponential enrichment) technique. The result was a 29-nucleotide aptamer, with a chemically modiÞ ed RNA backbone that increases nuclease resistance and a 5' terminus that includes a 40kD polyethylene glycol moiety for prolonged tissue residence [ Fig. 1 
Preclinical Findings
In rodent models,VEGF 164 (the rodent equivalent of human VEGF 165 ) acts as a potent inß ammatory cytokine, mediating both ischemia-induced neovascularization and diabetesinduced breakdown of the blood-retinal barrier (BRB). In these experiments, intravitreous pegaptanib was shown to signiÞ cantly reduce pathological neovascularization, while leaving physiological vascularization unimpaired 6 and was also able to reverse diabetes-induced BRB breakdown. 7 Moreover, VEGF 165 proved to be dispensable for mediating VEGF's role in protecting retinal neurons from ischemia-induced apoptosis. 8 These data suggested that intravitreous pegaptanib could provide a safe and eff ective treatment against both ocular neovascularization and diabetes-induced retinal vascular damage.
Clinical Studies Neovascular AMD
Pivotal clinical trial data have demonstrated that pegaptanib is both eff ective and safe for the treatment of neovascular AMD. These data were derived from two randomized, double-masked studies known jointly as the V.I.S.I.O.N. (VEGF Inhibition Study in Ocular Neovascularization) trials. 9, 10 A total of 1186 subjects with any angiographic subtypes of neovascular AMD were included. Patients received intravitreous injections of 0.3 mg, 1 mg or 3 mg pegaptanib or sham injections every six weeks for 48 weeks. Subjects with predominantly classic lesions could also have received photodynamic therapy with verteporÞ n (PDT; Visudyne TM , Novartis) at investigator discretion. Aft er one year, the 0.3 mg dose conferred a signiÞ cant clinical beneÞ t compared to sham treatment as measured by proportions of patients losing <15 lett ers of visual acuity (VA); compared with 55% (164/296) of patients receiving sham injections, 70% (206/294) of patients receiving 0.3 mg of pegaptanib met this primary endpoint (P < 0.001). In contrast to PDT, clinical beneÞ t was seen irrespective of angiographic AMD subtype, baseline vision or lesion size and led to the clinical approval of pegaptanib for the treatment of all angiographic subtypes of neovascular AMD. The 1 mg and 3 mg doses showed no additional beneÞ t beyond the 0.3 mg dose.
9 Treatment with 0.3 mg pegaptanib was also effi cacious as determined by mean VA change, proportions of patients gaining vision and likelihood of severe vision loss. In an extension of the V.I.S.I.O.N. study, patients in the pegaptanib arms were rerandomized to continue or discontinue therapy for 48 more weeks.
10 Compared to patients discontinuing pegaptanib or receiving usual care, those remaining on 0.3 mg pegaptanib received additional signiÞ cant clinical beneÞ t in the second year. Further subgroup analyses suggested that pegaptanib treatment was especially eff ective in those patients who were treated early in the course of their disease.
11
Pegaptanib showed an excellent safety proÞ le. All dosages were safe, with most adverse events attributable to the injection procedure rather than to the study drug itself. In the Þ rst year, serious adverse events occurred with <1% of intravitreous injections 9 and no new safety signals have been identiÞ ed in patients receiving pegaptanib for two and three years.
12,13 The frequencies of serious ocular adverse events for all three years are presented in Table 1 . 12, 13 In addition, no systemic safety signals have emerged over this period. These conclusions have also been conÞ rmed in assessments of systemic parameters following intravitreous injection of 1 mg and 3 mg pegaptanib.
14 Diabetic macular edema (DME) Safety and effi cacy of pegaptanib were assessed in a randomized, sham-controlled, double-masked, Phase 2 trial enrolling 172 diabetic subjects with DME aff ecting the center of the fovea. Intravitreous injections were administered at baseline and every six weeks thereaft er. At Week 36, 0.3 mg pegaptanib was signiÞ cantly superior to sham injection, as measured by mean change in VA (+4.7 lett ers vs. -0.4 lett ers, P=0.04), proportions of patients gaining ≥10 lett ers of VA (34% vs.10%; P=0.003), change in mean central retinal thickness (68µm decrease vs. 4 µm increase; P=0.02) and proportions of patients requiring subsequent photocoagulation treatment (25% vs. 48%, P=0.04).
15
In addition, a retrospective subgroup analysis revealed that pegaptanib treatment led to the regression of baseline retinal neovascularization in eight of 13 patients with proliferative diabetic retinopathy (PDR) whereas no such regression occurred in three sham-treated eyes or in four untreated fellow eyes. 16 Early results from a small, randomized, open-label study suggest that adding pegaptanib to panretinal photocoagulation conferred signiÞ cant clinical beneÞ t in patients with PDR.
17
Macular edema secondary to central retinal vein occlusion (CRVO) VEGF has been implicated in the pathophysiology of CRVO.
18
Accordingly, in a trial that enrolled subjects with CRVO of <6 months duration, 19 98 subjects were randomized (1:1:1) to receive intravitreous pegaptanib (0.3 mg or 1 mg) or sham injections every six weeks and panretinal photocoagulation if needed. At Week 30, treatment with 0.3 mg pegaptanib was superior in terms of mean change in VA, proportions of patients losing ≥15 lett ers from baseline, proportions with a Þ nal VA of ≥35 lett ers and reduction in center point and central subÞ eld thickness.
19,20
Investigational studies with pegaptanib Encouraging findings have been reported in small case series investigating the use of pegaptanib for the treatment of neovascular glaucoma, 21 retinopathy of prematurity 22 and familial exudative vitreoretinopathy. 23 In addition, given its positive safety profile, now validated over three years in clinical trials and two and a half years of postmarketing experience, pegaptanib is being studied as a maintenance Shukla et al.: Pegaptanib sodium for ocular vascular disease anti-VEGF inhibitor following induction with nonselective anti-VEGF agents such as ranibizumab or bevacizumab, which bind all VEGF isoforms 24,25 and appear to be associated with an increased, albeit small, risk of stroke.
26
Conclusions
Pegaptanib is both safe and clinically eff ective for the treatment of all angiographic subtypes of neovascular AMD. Early, wellcontrolled trials further suggest that pegaptanib may provide therapeutic beneÞ t for patients with DME, PDR and RVO. The roles that pegaptanib will ultimately play as part of the ophthalmologist's armamentarium remain to be established. The recent results with ranibizumab demonstrating the potential for signiÞ cant vision gains in AMD 27,28 have been impressive, but issues of safety remain to be definitively resolved;
26 combinatorial regimens may ultimately prove to be most eff ective in balancing safety with effi cacy. 24 Similarly, more established approaches, such as photodynamic therapy with verteporÞ n, may provide greater clinical beneÞ t when combined with anti-VEGF therapy, 29 so that there is likely to be considerable space for empiricism in determining the best approach for a given patient. Nonetheless, the overall trend is highly positive, with the anti-VEGF agents aff ording many more options than were available only a few years ago. Such successes highlight the importance of VEGF in the pathogenesis of ocular vascular disorders and support the use of anti-VEGF agents as foundation therapy in patients with these conditions. Indian Journal of Ophthalmology ) .
